BTSG Growth Drivers in 2026 Across Specialty and Providers

BrightSpring Health Services, Inc. BTSG enters 2026 with a business model built for one clear trend: more complex care moving out of hospitals and into the home. That shift expands demand for medication access, therapy management, and coordinated clinical services in lower-cost settings.

After strong execution in 2025, management expects sequential improvement through 2026 as mix and efficiency initiatives build, and profitability grows faster than revenue.

BTSG Overview of the Home-Based Care Platform

BrightSpring operates a national, home- and community-based platform that integrates pharmacy capabilities with hands-on provider care for medically complex patients across Medicare, Medicaid, and commercial payors. The company is headquartered in Louisville, KY, and serves all 50 states.

Operations are organized into two reporting segments. Pharmacy Solutions focuses on medication dispensing and therapy management across specialty, infusion, senior living, hospice, skilled nursing facilities, and hospital discharges. Provider Services delivers clinical and supportive care primarily in the home, including home health, hospice, rehabilitation therapy, home-based primary care, and personal care support tied to activities of daily living and social determinants.

Scale is a differentiator. Management reports serving more than 465,000 patients daily through approximately 10,500 clinical providers and pharmacists, with pharmacy and provider operations co-located across nearly 40 states to support integrated care pathways and value-based models.

BrightSpring Revenue Mix and Segment Role Clarity

In fiscal 2025, revenue reached $12.9 billion, up 28.2% from $10.1 billion in 2024. Pharmacy Solutions generated $11.4 billion, or 88.7% of total revenue, compared with $8.8 billion and 86.9% in 2024. Provider Services contributed $1.5 billion, or 11.3%, versus $1.3 billion and 13.1% in 2024.

Within Pharmacy Solutions, specialty and infusion rose to $9.1 billion from $6.5 billion, while home and community pharmacy increased to $2.4 billion from $2.2 billion. The shift toward Pharmacy Solutions as a larger share of the total reflects the faster growth trajectory in specialty and infusion.

The 2025 payor mix also underscores broad exposure. Medicare Part D represented nearly 31.7% of revenue, Medicare Advantage about 17.6%, commercial nearly 24.1%, and Medicaid roughly 8.5%. Provider Services is split across Medicare Part A, Medicaid, commercial, and other Medicare categories.

BrightSpring Health Services, Inc. Price and Consensus

BrightSpring Health Services, Inc. price-consensus-chart | BrightSpring Health Services, Inc. Quote

BTSG Specialty and Infusion as the Growth Engine

Specialty and infusion are positioned as the primary growth catalysts, supported by limited-distribution drug access and a deep launch pipeline. Management highlighted an LDD portfolio that reached 149 drugs, and fourth-quarter specialty and infusion growth of 43% year over year, supported by new LDD wins and expanding fee-for-service capabilities.

Looking ahead, management flagged expectations for more than 16–20 limited-distribution launches over the next 12–18 months. That cadence matters because LDD access can drive both script volume and higher-value clinical management work inside the pharmacy model.

Infusion is also central to the 2026 setup. Management expects 3–4 infusion LDD awards in the first quarter or early second quarter of 2026, while acute infusion is described as continuing to grow at double-digit rates.

BrightSpring Margin Expansion Levers for 2026

The margin narrative for 2026 ties directly to several operational levers. Management points to mix shift toward higher-value specialty and infusion work, efficiency programs, automation, pricing initiatives, cross-sell, and scale benefits as drivers of rising profitability.

A midyear generic launch expected in the second quarter of 2026 is another key contributor. The company also expects ambulatory infusion suite upgrades to support mix and margins as the year progresses.

Importantly, management expects Adjusted EBITDA to grow faster than revenue in 2026, signaling company-level margin expansion even with policy and product-mix headwinds in the top line. Guidance calls for 2026 revenue of $14.45 billion to $15.0 billion and adjusted EBITDA of $760 million to $790 million.

BTSG Provider Services Growth and Integration Upside

Provider Services is framed as a 2026 accelerator, with guidance language pointing to segment revenue growth in the mid-to-high twenties percentage points. Growth is supported by de novos and the December 2025 close of the Amedisys/LHC assets.

The acquired assets are expected to contribute about $30 million of Adjusted EBITDA in 2026, while integration and technology standardization proceed. Management describes Provider Services as a roughly 17% margin business and aims to move acquired home health margins toward that profile over time.

This matters for consolidated performance because it adds another growth leg that can strengthen durability, especially as the company invests in integrating clinical operations with the broader home-based platform.

BrightSpring Home and Community Pharmacy Stabilization Path

Home and community pharmacy faces near-term headwinds that are expected to pressure script growth through the third quarter of 2026. The pressures are tied to offboarded uneconomic customers and a customer bankruptcy unwind.

Management’s mitigation plan focuses on targeted end markets, including assisted living, hospice, behavioral, Programs of All-Inclusive Care for the Elderly, and targeted skilled nursing facilities. The plan also includes nearly 30 new sales hires in 2026 and multiple intake and revenue-cycle automation projects to improve conversion and operational consistency.

Pricing initiatives are also part of the offset strategy, including efforts to enhance dispensing fees with payors and lean initiatives to protect margins. Stabilization is expected later in 2026 as these actions scale and the headwinds are lapped.

BTSG What to Watch Quarter to Quarter in 2026

First, track the cadence of limited-distribution drug wins and whether the expected 16–20 launch pipeline converts on schedule. Infusion-specific progress should be visible in updates around the anticipated 3–4 infusion LDD awards expected in early 2026.

Second, watch the timing and profit impact of the generic launch expected in the second quarter of 2026, alongside signs that mix and efficiency efforts are translating into sequential margin improvement as the year progresses.

Third, monitor integration milestones and technology standardization tied to the Amedisys/LHC assets, including the pace of margin normalization and contribution toward the targeted $30 million of Adjusted EBITDA in 2026.

In the broader home-based care landscape, competitive intensity remains high. Option Care Health OPCH is a large independent home infusion provider, while CVS Health CVS operates a major specialty pharmacy franchise, keeping execution and access wins critical differentiators for BTSG as 2026 unfolds.

BTSG presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CVS Health Corporation (CVS): Free Stock Analysis Report

Option Care Health, Inc. (OPCH): Free Stock Analysis Report

BrightSpring Health Services, Inc. (BTSG): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research